Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells

The development of Imatinib mesylate (IM), which targets the oncogenic BCR-ABL fusion protein, has greatly improved the outcome of Chronic Myeloid Leukemia (CML) patients. However, BCR-ABL–positive progenitors can be detected in CML patients in complete cytogenetic response. Several evidence suggest...

Descripción completa

Detalles Bibliográficos
Autores principales: Salati, Simona, Salvestrini, Valentina, Carretta, Chiara, Genovese, Elena, Rontauroli, Sebastiano, Zini, Roberta, Rossi, Chiara, Ruberti, Samantha, Bianchi, Elisa, Barbieri, Greta, Curti, Antonio, Castagnetti, Fausto, Gugliotta, Gabriele, Rosti, Gianantonio, Bergamaschi, Micaela, Tafuri, Agostino, Tagliafico, Enrico, Lemoli, Roberto, Manfredini, Rossella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564781/
https://www.ncbi.nlm.nih.gov/pubmed/28533480
http://dx.doi.org/10.18632/oncotarget.17706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564781/
https://www.ncbi.nlm.nih.gov/pubmed/28533480
http://dx.doi.org/10.18632/oncotarget.17706

Ejemplares similares